Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Accumulated Expenses: 2022-2024

Historic Other Accumulated Expenses for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $752,000.

  • Taysha Gene Therapies' Other Accumulated Expenses fell 14.50% to $749,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $749,000, marking a year-over-year decrease of 14.50%. This contributed to the annual value of $752,000 for FY2024, which is 4.01% up from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Other Accumulated Expenses is $752,000, which was up 4.01% from $723,000 recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Other Accumulated Expenses registered a high of $752,000 during FY2024, and its lowest value of $650,000 during FY2022.
  • For the 3-year period, Taysha Gene Therapies' Other Accumulated Expenses averaged around $708,333, with its median value being $723,000 (2023).
  • Data for Taysha Gene Therapies' Other Accumulated Expenses shows a peak YoY grew of 11.23% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Taysha Gene Therapies' Other Accumulated Expenses stood at $650,000 in 2022, then climbed by 11.23% to $723,000 in 2023, then increased by 4.01% to $752,000 in 2024.